Markus Puhlmann - 02 Mar 2026 Form 4 Insider Report for Perspective Therapeutics, Inc. (CATX)

Reporting relationship: Chief Medical Officer
Issuer ticker: CATX
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 16:34:56 UTC
Prior SEC filing: 05 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Markus Puhlmann by Chris Nenno, as Attorney-in-Fact

Key filing fact

Markus Puhlmann filed Form 4 for Perspective Therapeutics, Inc. (CATX) on 04 Mar 2026.

Key facts

This page summarizes Markus Puhlmann's Form 4 filing for Perspective Therapeutics, Inc. (CATX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2026, 16:34.

Change

Previous filing in this sequence was filed on 05 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001965071 Primary reporting owner

Puhlmann Markus

Relationship: Chief Medical Officer
Address: C/O PERSPECTIVE THERAPEUTICS, INC., 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE
Signature: /s/ Markus Puhlmann by Chris Nenno, as Attorney-in-Fact
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CATX transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +150,000
Change %
Price: $0.000000^*
Shares after: 150,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $5.35
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

Footnote F2

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.